224 related articles for article (PubMed ID: 26997655)
1. Safety and efficacy of valproic acid treatment in SCA3/MJD patients.
Lei LF; Yang GP; Wang JL; Chuang DM; Song WH; Tang BS; Jiang H
Parkinsonism Relat Disord; 2016 May; 26():55-61. PubMed ID: 26997655
[TBL] [Abstract][Full Text] [Related]
2. Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4.
Yi J; Zhang L; Tang B; Han W; Zhou Y; Chen Z; Jia D; Jiang H
PLoS One; 2013; 8(1):e54792. PubMed ID: 23382971
[TBL] [Abstract][Full Text] [Related]
3. A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease.
Saute JA; de Castilhos RM; Monte TL; Schumacher-Schuh AF; Donis KC; D'Ávila R; Souza GN; Russo AD; Furtado GV; Gheno TC; de Souza DO; Portela LV; Saraiva-Pereira ML; Camey SA; Torman VB; de Mello Rieder CR; Jardim LB
Mov Disord; 2014 Apr; 29(4):568-73. PubMed ID: 24399647
[TBL] [Abstract][Full Text] [Related]
4. Planning future clinical trials in Machado Joseph disease: Lessons from a phase 2 trial.
Saute JA; Rieder CR; Castilhos RM; Monte TL; Schumacher-Schuh AF; Donis KC; D'Ávila R; Souza GN; Russo AD; Furtado GV; Gheno TC; Souza DO; Saraiva-Pereira ML; Portela LV; Camey S; Torman VB; Jardim LB
J Neurol Sci; 2015 Nov; 358(1-2):72-6. PubMed ID: 26297649
[TBL] [Abstract][Full Text] [Related]
5. Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.
Watchon M; Luu L; Robinson KJ; Yuan KC; De Luca A; Suddull HJ; Tym MC; Guillemin GJ; Cole NJ; Nicholson GA; Chung RS; Lee A; Laird AS
Mol Brain; 2021 Aug; 14(1):128. PubMed ID: 34416891
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance spectroscopy of the cerebellum in patients with spinocerebellar ataxia type 3/Machado-Joseph disease.
Lei L; Liao Y; Liao W; Zhou J; Yuan Y; Wang J; Jiang H; Shen L; Tang B
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 36(6):511-9. PubMed ID: 21743142
[TBL] [Abstract][Full Text] [Related]
7. Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease.
Schulte T; Mattern R; Berger K; Szymanski S; Klotz P; Kraus PH; Przuntek H; Schöls L
Arch Neurol; 2001 Sep; 58(9):1451-7. PubMed ID: 11559318
[TBL] [Abstract][Full Text] [Related]
8. Planning Future Clinical Trials for Machado-Joseph Disease.
Saute JAM; Jardim LB
Adv Exp Med Biol; 2018; 1049():321-348. PubMed ID: 29427112
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3.
Zesiewicz TA; Greenstein PE; Sullivan KL; Wecker L; Miller A; Jahan I; Chen R; Perlman SL
Neurology; 2012 Feb; 78(8):545-50. PubMed ID: 22323747
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Therapies for Machado-Joseph Disease.
Duarte-Silva S; Maciel P
Adv Exp Med Biol; 2018; 1049():369-394. PubMed ID: 29427114
[TBL] [Abstract][Full Text] [Related]
11. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
Piepers S; Veldink JH; de Jong SW; van der Tweel I; van der Pol WL; Uijtendaal EV; Schelhaas HJ; Scheffer H; de Visser M; de Jong JM; Wokke JH; Groeneveld GJ; van den Berg LH
Ann Neurol; 2009 Aug; 66(2):227-34. PubMed ID: 19743466
[TBL] [Abstract][Full Text] [Related]
12. Spin labeling artery method perfusion MRI study of SPG4 and SCA3/MJD.
Xing W; Wang XY; Liao XX; Liao WH; Shen L
Magn Reson Imaging; 2014 Dec; 32(10):1330-4. PubMed ID: 25172988
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of NSE and S100B in spinocerebellar ataxia type 3/Machado-Joseph disease.
Zhou J; Lei L; Shi Y; Wang J; Jiang H; Shen L; Tang B
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 36(6):504-10. PubMed ID: 21743141
[TBL] [Abstract][Full Text] [Related]
14. Spinocerebellar ataxia type 3/Machado-Joseph disease starting before adolescence.
Donis KC; Saute JA; Krum-Santos AC; Furtado GV; Mattos EP; Saraiva-Pereira ML; Torman VL; Jardim LB
Neurogenetics; 2016 Apr; 17(2):107-13. PubMed ID: 26780339
[TBL] [Abstract][Full Text] [Related]
15. Case report: Short-term efficacy and changes in
Cui Z; Lan Y; Chang Y; Liu X; Wang J; Lou X; Wang R
Front Neurol; 2023; 14():1246430. PubMed ID: 37830087
[TBL] [Abstract][Full Text] [Related]
16. Glucocerebrosidase gene variants in parkinsonian patients with Machado Joseph/spinocerebellar ataxia 3.
Siebert M; Donis KC; Socal M; Rieder CR; Emmel VE; Vairo F; Michelin-Tirelli K; França M; D'Abreu AC; Bettencourt C; Lima M; Lopes Cendes I; Saraiva-Pereira ML; Jardim LB
Parkinsonism Relat Disord; 2012 Feb; 18(2):185-90. PubMed ID: 22001711
[TBL] [Abstract][Full Text] [Related]
17. Cognitive deficits in Machado-Joseph disease correlate with hypoperfusion of visual system areas.
Braga-Neto P; Dutra LA; Pedroso JL; Felício AC; Alessi H; Santos-Galduroz RF; Bertolucci PH; Castiglioni ML; Bressan RA; de Garrido GE; Barsottini OG; Jackowski A
Cerebellum; 2012 Dec; 11(4):1037-44. PubMed ID: 22307858
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
Atmaca A; Al-Batran SE; Maurer A; Neumann A; Heinzel T; Hentsch B; Schwarz SE; Hövelmann S; Göttlicher M; Knuth A; Jäger E
Br J Cancer; 2007 Jul; 97(2):177-82. PubMed ID: 17579623
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.
Chou AH; Chen SY; Yeh TH; Weng YH; Wang HL
Neurobiol Dis; 2011 Feb; 41(2):481-8. PubMed ID: 21047555
[TBL] [Abstract][Full Text] [Related]
20. Fatigue and Its Associated Factors in Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.
Martinez AR; Nunes MB; Faber I; D'Abreu A; Lopes-Cendes Í; França MC
Cerebellum; 2017 Feb; 16(1):118-121. PubMed ID: 27021342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
